Eco Animal Health (GB:EAH) has released an update.
Eco Animal Health Group PLC is on the verge of securing US approval for ECOVAXXIN® MS, their new poultry vaccine against Mycoplasma synoviae, after passing a critical internal risk assessment reviewed by the USDA. The company, known for its veterinary pharmaceuticals and vaccines, anticipates a US launch of the vaccine by late 2025, marking a significant step in its R&D pipeline expansion. Collaboration with the Poultry Diagnostic & Research Center at the University of Georgia has been instrumental in developing this non-pathogenic vaccine strain, which meets the USDA’s stringent safety standards and lacks antimicrobial resistance genes.
For further insights into GB:EAH stock, check out TipRanks’ Stock Analysis page.
